PAM
WST icon

Paradigm Asset Management’s West Pharmaceutical WST Stock Holding History

Paradigm Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-600
Closed -$56.7K – 518
2017
Q2 		$56.7K Sell
600
-700
-54% -$64.4K 0.01% 508
2017
Q1 		$106K Sell
1,300
-400
-24% -$33.4K 0.02% 513
2016
Q4 		$144K Sell
1,700
-100
-6% -$7.86K 0.03% 331
2016
Q3 		$134K Buy
+1,800
New +$143K 0.02% 363
2014
Q3 		– Sell
-36,700
Closed -$1.55M – 873
2014
Q2 		$1.55M Buy
36,700
+2,400
+7% +$103K 0.21% 149
2014
Q1 		$1.51M Sell
34,300
-2,600
-7% -$122K 0.21% 149
2013
Q4 		$1.81M Sell
36,900
-37,700
-51% -$1.76M 0.28% 133
2013
Q3 		$3.07M Buy
74,600
+2,600
+4% +$99.2K 0.5% 51
2013
Q2 		$2.53M Buy
+72,000
New +$2.37M 0.43% 74

Other funds holding WST

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Paradigm Asset Management's WST Position: Q3 2017 in Review

Paradigm Asset Management sold out of West Pharmaceutical (WST) in Q3 2017, closing a stake of 600 shares — an estimated $56.7K sold.

Paradigm Asset Management first reported a position in WST in Q2 2013 and held it in 9 quarters. The position peaked at $3.07M in Q3 2013. 302 funds tracked by Wall St. Rank hold WST as of Q3 2017.

  • Paradigm Asset Management reported no remaining West Pharmaceutical position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 600 West Pharmaceutical shares in Q3 2017, an estimated $56.7K.
  • Paradigm Asset Management first reported a position in West Pharmaceutical in Q2 2013 and held it in 9 quarters.
  • Paradigm Asset Management's West Pharmaceutical position peaked at $3.07M in Q3 2013.
  • 302 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.